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Robust TLR4-induced gene expression patterns
are not an accurate indicator of human immunity
Kelly L Brown1,2,4*, Reza Falsafi1, Winnie Kum1, Pamela Hamill1, Jennifer L Gardy1, Donald J Davidson2,3,
Stuart Turvey2, Brett B Finlay1, David P Speert2, Robert EW Hancock1
Abstract
Background: Activation of Toll-like receptors (TLRs) is widely accepted as an essential event for defence against
infection. Many TLRs utilize a common signalling pathway that relies on activation of the kinase IRAK4 and the
transcription factor NFB for the rapid expression of immunity genes.
Methods: 21 K DNA microarray technology was used to evaluate LPS-induced (TLR4) gene responses in blood
monocytes from a child with an IRAK4-deficiency. In vitro responsiveness to LPS was confirmed by real-time PCR
and ELISA and compared to the clinical predisposition of the child and IRAK4-deficient mice to Gram negative
infection.
Results: We demonstrated that the vast majority of LPS-responsive genes in IRAK4-deficient monocytes were
greatly suppressed, an observation that is consistent with the described role for IRAK4 as an essential component
of TLR4 signalling. The severely impaired response to LPS, however, is inconsistent with a remarkably low incidence
of Gram negative infections observed in this child and other children with IRAK4-deficiency. This unpredicted
clinical phenotype was validated by demonstrating that IRAK4-deficient mice had a similar resistance to infection
with Gram negative S. typhimurium as wildtype mice. A number of immunity genes, such as chemokines, were
expressed at normal levels in human IRAK4-deficient monocytes, indicating that particular IRAK4-independent
elements within the repertoire of TLR4-induced responses are expressed.
Conclusions: Sufficient defence to Gram negative immunity does not require IRAK4 or a robust, ‘classic’
inflammatory and immune response.
Background
Toll-like receptor-4 (TLR4) is a prominent member of
the TLR family of host receptors that recognize micro-
bial components in the intra- and extra-cellular environ-
ment [1,2]. Lipopolysaccharide (LPS, endotoxin) is a
major component of the cell wall of Gram negative bac-
teria, a potent TLR4 agonist and the driving force
behind sepsis. TLR4 engagement by LPS results in the
activation of the transcription factor NFB via signal
transduction cascades that are propagated either
through, or independent of, the adaptor molecule
MyD88 [2-4]. Organisms amenable to genetic manipula-
tion have been used to evaluate the importance of TLR4
and various downstream signalling molecules for the
(LPS-)induced expression of immunity genes (most
commonly cytokines including chemokines) and defence
against various pathogens [5,6], e.g., MyD88-knockout
mice fail to elevate serum cytokines when administered
a high dose of LPS and are susceptible to infection by S.
aureus [7], P. aeruginosa [8], M. tuberculosis [9], M.
avium [10] and L. monocytogenes [11]. Such studies
have established that the MyD88-dependent pathway,
via sequential activation of IRAK4, IRAK1, TRAF6, IKK
and NFB, drives a cellular response to TLR agonists
that is responsible for the robust expression of early-
response, NFB-regulated immunity genes. It has been
often assumed that this robust transcriptional response,
involving the substantial induction of a large number of
genes (>1000) is essential for normal immunological
function(s) and, in turn, host defences. Moreover, the
reduced expression, either in vitro or in vivo, of just a
subset of TLR-responsive genes, such as the classic pro-
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inflammatory cytokines (TNF-a, IL-6), chemokines (IL-
8, Gro-a/CXCL1) and antibacterials (antimicrobial pep-
tides, reactive oxygen/nitrogen species) is often accepted
as sufficient evidence to predict a defect in host defence
against infectious agents.
Since 2003, eighteen individuals, primarily children,
have been identified with a mutation in the gene that
encodes IL-1R-associated kinase 4 (IRAK4) that lies
immediately downstream of MyD88 in the TLR signal-
ling cascade (reviewed in [12]). We previously reported
an IRAK4-deficiency in a 4-year old child due to a
homozygous single base substitution (C887T) in exon 8
of the IRAK4 gene that introduced a premature stop
codon (Q293X) [13,14]; an identical mutation occurs in
the majority of cases of IRAK4 immunodeficiency.
PBMC from children with IRAK4-deficiency consistently
show impaired in vitro responsiveness, as measured by
the production of pro-inflammatory cytokines, to
selected TLR agonists [12-14]. Given the pivotal position
of IRAK4 in the TLR pathway and the failed responsive-
ness of IRAK4-deficient (human and mouse) cells to
both Gram positive (LTA, PGN) and Gram negative
(LPS) TLR agonists, it seemed logical that a defect in
IRAK4 would render patients susceptible to a broad
range of both Gram positive and Gram negative bacter-
ial pathogens. In contrast, children with an IRAK4-defi-
ciency have a remarkably mild immunodeficiency with
enhanced susceptibility to infection by only a narrow
range of Gram positive bacteria, particularly S. aureus
and S. pneumoniae [12-18]. IRAK4 knockout mice are
also more susceptible to infections by (Gram positive) S.
aureus than wild-type mice [19]. We were intrigued by
the relatively small number of documented cases of
Gram negative infections in IRAK4-deficient children
[20,21] in light of a consistently poor cellular responses
to LPS. It should be noted that these children are pre-
scribed a regimen of antibiotics that are effective only
against Gram positive bacteria, thus prophylaxis can not
explain their apparent immunity to Gram negative infec-
tions. IRAK4 knockout mice and IRAK4-kinase-dead
knock-in mice also fail, in vitro and in vivo, to produce
inflammatory cytokines in response to LPS and are pro-
tected against LPS-induced sepsis in vivo [19,22-24].
There is, however, a resounding lack of experimental
evidence that IRAK4-deficiency (in humans or mice)
actually compromises host defences to Gram negative
infection.
Herein we provide the first evidence that IRAK4
knockout mice are not overwhelmed by challenge with
the Gram negative bacterium S. typhimurium. These
results substantiated our hypothesis that the under-
whelming number of documented Gram negative bac-
terial infections in IRAK-deficient children is likely
attributable to sufficient host defence. The widely
accepted notion that the absence of IRAK4 should com-
promise immunity to Gram negative pathogens was
based primarily upon results demonstrating the compro-
mised expression of a small number of classic LPS-
responsive, pro-inflammatory markers (primarily cyto-
kines) as well as the assumption that high expression of
these genes in particular was required for immunity.
Here we evaluated the impact of IRAK4-deficiency on a
global scale using 21 K microarray technology to analyze
total gene expression in LPS-activated monocytes from
an IRAK4-deficient patient. In accordance with previous
reports, and counter-intuitive to a resistance to Gram
negative infection, there was a profound failure of
IRAK4-deficient monocytes to produce, in response to
LPS, substantial levels of classical immunity genes (cyto-
kines, chemokines, NFB subunits). Upon closer exami-
nation, however, it was discovered that the expression of
these genes, while low, was seldom abolished. Moreover,
approximately 20% of LPS-responsive genes, including
certain chemokines, transcription factors and regulators
of translation, were expressed at similar levels in control
and IRAK4-deficient cells. We conclude that IRAK4 is
indeed essential for LPS-induced signal transduction via
the MyD88-dependent pathway that is responsible for
rapid and vigorous transcription of classical NFB-regu-
lated immunity genes, but that neither IRAK4 nor a
robust transcriptional response (typical of cells exposed
to LPS) are required for immunity to Gram negative
infections.
Methods
PBMC isolation and stimulation
PBMC from healthy volunteers and the patient were
prepared as previously described [25], in accordance
with UBC Clinical Research Ethics Board protocol C04-
0193. Due to the rarity of this syndrome only a single
patient was available to us; however previous studies
have demonstrated similar phenotypic responses for
most IRAK4 deficient patients including this one
[13-18]. PBMC (2-3 × 107 cells at 5 × 106 cells/ml) were
stimulated for 4 hr at 37°C 5% CO2 with 100 ng/ml
Escherichia coli 0111:B4 LPS (Invivogen). Based on pre-
vious studies, LPS-induced gene transcription in mono-
cytes peaked (with respect to the number of genes and
the magnitude of gene expression) after 4 hr of stimula-
tion, at which point a substantial level of inflammatory
cytokines could also be detected in the tissue culture
supernatant [25]. We previously reported comparable
cytokine responses in PBMC isolated from adults and
children following in vitro stimulation with TLR ago-
nists [26]; thus for ethical reasons we used adult PBMC
as controls in these experiments. All reagents were
tested for the absence of endotoxin and reconstituted in
endotoxin-free water.
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Detection of cytokines and chemokines
Following culture of PBMC, the tissue culture superna-
tants were centrifuged and stored at -80°C and/or mea-
sured for cytokines using a cytokine 5-Plex kit (Biosource
International Inc) and Luminex 100™ StarStation software
(Applied Cytometry Systems) as described [25]. CCL22
(MDC) secretion in tissue culture supernatants was
detected with a capture ELISA (R&D Systems).
Positive selection of CD14+ monocytes and DNA
microarrays
Following culture of PBMC, monocytes were positively
selected using anti-CD14 conjugated magnetic beads
(M450; Dynal; Invitrogen) as described [27,28]. RNA
was isolated from monocytes with RNeasy Mini kit and
analyzed using an Agilent 2100 Bioanalyzer (Agilent
Technologies) as described [25]. Equal quantities of
RNA from each of five healthy individuals were pooled
per experimental condition to generate a reference sam-
ple of the average (n = 5) expression of genes in control
monocytes. The profile of LPS-responsive gene expres-
sion in the control pool was consistent with what has
been observed by us in monocytes from individual sub-
jects [29]. Microarray analyses were performed on
21,000 gene arrays as previously described [29], analyzed
by ArrayPipe software, version 1.6 [30], and the data
deposited into ArrayExpress under accession number E-
FPMI-7. Differentially expressed genes were overlayed
on known signal transduction pathways using Cytos-
cape, an open-source bioinformatics visualization soft-
ware [31]. The Gene Ontology Tree Machine software
[32] was used to identify gene ontology (GO) categories
and biological processes with a significantly enriched
(ratio >1.0 and p < 0.01) number of differentially
expressed genes (indicative of dysregulation) in the
patient’s monocytes.
Quantitative real-time PCR (qPCR)
Differential gene expression was validated using the
SuperScript™ III Platinum® Two-Step qRT-PCR Kit with
SYBR® Green (Invitrogen) [25], using 10 ng of total
RNA as the starting material. Reported fold changes in
gene expression were normalized to GAPDH in each
sample and were relative to the expression of the gene
in resting control monocytes. The result of qPCR ana-
lyses of more than twenty, TLR-inducible, NFB-regu-
lated genes was in agreement with the microarray gene
expression data 84% of the time; a correlation indicative
of a reliable microarray data set with a relatively low
incidence of false results.
Bacterial culture and infection of mice
IRAK4-/- mice on the C57BL/6 background [19] were
obtained from the Canadian Network for Vaccines and
Immunotherapeutics of Cancer and Chronic Viral Dis-
eases (CanVac). Sex- and age-matched control C57BL/6
mice were purchased from Jackson Laboratories (Bar
Harbor, Maine). Animals were used at 8-10 weeks of
age. Studies were performed under pathogen-free condi-
tions according to the standard animal care guidelines
and protocols of the UBC Animal Care Committee and
Canadian Council on Use of Laboratory Animals. Sal-
monella serovar Typhimurium wild-type strain SL1344
[33] was grown with overnight shaking (220 rpm) in 3
ml Luria-Bertani (LB) broth with 50 μg/ml streptomycin
at 37°C for 18 hr. Groups of eight mice were infected by
oral gavage with approximately 1 × 107 CFU in 100 μl
of sterile PBS. Infected mice were monitored twice daily.
Mice that showed extreme distress or became moribund
were euthanized and survival of the animals was
recorded.
Results
IRAK4-deficient mice survive infection by the Gram
negative pathogen Salmonella typhimurium
To validate the unusually low occurrence of Gram-nega-
tive infections in IRAK4-deficient children, IRAK4-defi-
cient mice were challenged with the Gram negative
bacterium, S. typhimurium. Results shown in Figure 1
demonstrated no significant difference in survival rates
between IRAK4-deficient mice and wild type mice fol-
lowing challenge with S. typhimurium. Thus, the
absence of IRAK4 does not render animals defenceless
against a Gram negative bacterial challenge. These data
together with that of Suzuki et al demonstrated that
IRAK4 knockout mice are highly susceptible to Gram
positive [19] but not necessarily Gram negative bacterial
infections (Figure 1), an infection profile that emulates
that of children with an IRAK4 deficiency. Thus these
data strengthen our hypothesis that immunity, as
opposed to prophylaxis or a lack of exposure to Gram
negative bacteria, is responsible for the underwhelming
number of documented Gram negative infections in
children with IRAK4-deficiency.
Gene expression was generally severely compromised in
IRAK4-deficient monocytes stimulated with LPS
The long-standing assumption that any deficiency in the
major TLR to NFB pathway (such as an IRAK4-defi-
ciency) would compromise immunity to Gram negative
bacteria [34-36] was based on a substantial amount of
published data demonstrating compromised expression
in vitro of a limited set of LPS-induced, early-response,
NFB-regulated, pro-inflammatory markers in cells defi-
cient for various components of the TLR to NFB path-
way (including IRAK4). A functional genomics approach
was utilized here to view the broader impact of an
IRAK4 deficiency on LPS-induced gene expression.
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Blood monocytes were obtained from an IRAK4-defi-
cient child and subsequently stimulated in vitro in two
independent experiments, two months apart. With
human 21 K oligo-based DNA microarray technology,
the expression of genes in IRAK4-deficient monocytes
from each sampling was evaluated, in triplicate, relative
to gene expression in monocytes from five healthy indi-
viduals. Previous studies that employed a similar metho-
dology [28,29] served as a reference to confirm normal
LPS-responsive gene expression in the healthy, control
pool of monocytes.
The expression of more than 500 genes in IRAK4-defi-
cient cells stimulated with LPS was significantly different
compared to that in control cells (567 genes, differential
fold change ± 1.5, Student’s t-test p-value ≤ 0.05, results
deposited in ArrayExpress, accession number E-FPMI-7).
An overlay of the gene expression data on a protein map
of the TLR-to-NFB signal transduction pathway illu-
strated that the majority of differentially expressed genes
associated with this pathway were i) suppressed relative
to gene expression in control monocytes and ii) tended
to congregate downstream of the IB-NFB complex
(Figure 2). Gene ontology (GO) analysis [32] of the differ-
entially expressed genes predicted that 56 GO categories
were perturbed in IRAK4-deficient patients; these consti-
tuted 5 major biological processes (p < 0.01) namely
‘immune response’, ‘response to biotic stimulus’,
‘response to stress’, ‘cell adhesion’ and ‘negative regula-
tion of cellular processes’ (data not shown).
Thus, the microarray analysis of monocytes from an
IRAK4-deficient child revealed a substantial disturbance
in LPS-induced gene expression, in particular in genes
regulated by the TLR-to-NFB pathway and associated
with biological processes related to immunity and cellu-
lar responsiveness to stimuli. This global analysis of
gene expression in IRAK4-deficient monocytes was in
accordance with previously published results that ana-
lyzed small subsets of inflammatory genes/proteins and
confirmed the previously ascribed role of IRAK4 in
mediating signalling from TLR4 to genes downstream of
NFB.
Figure 1 IRAK4-deficient mice maintain defence against Gram
negative bacteria. IRAK4 -/- (dotted line) and age- and sex-
matched C57BL wild type (solid line) mice were infected with S.
typhimurium SL1344 and monitored for survival (y-axis) over time (x-
axis). The result is representative of two independent experiments
where lack of statistical significance (p = 0.69 and p = 0.13) for
differential survival between two groups of eight infected mice was
determined by the chi-square test.
Figure 2 Differentially expressed genes in LPS-stimulated IRAK4-deficient monocytes downstream of NFB. Using the open-source
bioinformatics visualization software Cytoscape [31] gene expression in LPS-stimulated, IRAK4-deficient monocytes was overlayed on the TLR4
signal transduction pathway downstream of NFB. Gene names are given in the left panel and gene expression in the right panel. The relative
expression of the gene in IRAK4-deficient monocytes is depicted by the colour of the nodes on the protein map; green nodes indicate lower
expression and red nodes indicate higher expression in IRAK4-deficient monocytes relative to that in a control pool of monocytes.
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Expression of NFB-regulated, pro-inflammatory genes
was compromised to varying degrees in IRAK4-deficient
monocytes
Cytokines, chemokines and certain antimicrobial pep-
tides are TLR-sensitive, early response genes of the
innate immune system that are commonly used to pre-
dict host defence and infectious disease risk. A subset of
these TLR-to-NFB-regulated immunity genes revealed
in the microarray analyses were selected for further
investigation. Genes were selected if they fit one or
more of the following criteria (i) the gene was regulated
by cellular activation with LPS (ii) the gene was a classic
pro-inflammatory mediator, for e.g., a cytokine (TNF-a,
IL-6), chemokine (IL-8, Gro-a/CXCL1) or antibacterial
(DEFB1) (iii) in previously published work, alteration of
the expression of the gene or protein product, either in
vitro or in vivo, was predicted to influence host defence,
or (iv) the gene served as an internal control (for e.g.,
induction of NFB subunits). Real-time quantitative
PCR (qPCR) and ELISA were used to confirm the
microarray results for relative gene expression between
control and IRAK4-deficient monocytes, and to establish
the absolute expression of mRNA and protein prior to
and following stimulation with LPS.
The expression of classic pro-inflammatory cytokines
and chemokines including TNF-a, IL-6, IL-12b, IL-8,
Gro-a/CXCL1, MCP-2/CCL8 and MIP-3a/CCL20 was
compromised in LPS-stimulated IRAK4-deficient mono-
cytes compared to LPS-stimulated control monocytes
(Figure 3 and Table 1). While the expression of these
genes was unanimously compromised, the degree of
suppression varied considerably, from 5- to 100- fold
reduction in expression (Figure 3A, Table 1). The rela-
tive level of protein expressed by PBMC was also heavily
compromised (ELISA shown for TNF-a, IL-8, IL-6 in
Figure 3B). These data were consistent with previous
reports of low levels of cytokines detected in the TCS of
LPS-stimulated PBMC from this patient and other indi-
viduals with mutations in the IRAK4 gene [12-18] as
well as diminished, but not absent levels of TNF-a and
IL-6 in the serum of IRAK4-kinase dead (KD) knockin
mice following in vivo administration of LPS [37]. These
data (Figure 2, Figure 3, Table 1) illustrated that gene
transcription and protein secretion of key pro-inflamma-
tory mediators, while highly variable, was not completely
abolished in IRAK4-deficient monocytes exposed to LPS.
Identification of LPS-responsive, IRAK4-independent
immunity genes
While LPS-induced expression of the majority of NFB-
regulated genes was lowered in IRAK4-deficient mono-
cytes, the TLR-to-NFB pathway map (shown in Figure
2) revealed a subset of genes that were expressed at
similar (white nodes) or higher (red nodes) levels in
IRAK4-deficient and control cells. It was discovered that
approximately 20% of LPS-responsive genes were
expressed in IRAK4-deficient monocytes in a similar
manner to that observed in control cells. A subset of
LPS-responsive genes associated with host defence that
were induced or suppressed to a similar extent (<1.2
fold difference) in control and IRAK4-deficient mono-
cytes are listed in Table S1, Additional file 1 (microarray
data). Genes of this nature encoded a diverse range of
proteins involved in immunity including, but not
restricted to, chemokines (MDC/CCL22), antibacterial
agents (DEFB1), transcription factors (FOS, JUN, RELB),
cytokine receptors (IL13RA1) and mRNA-destabilizing
agents (ZFP36L2). The uncompromised expression of
these genes in IRAK4-deficient cells was confirmed by
qPCR (Table 1).
The relatively normal expression of the chemoattrac-
tant MDC/CCL22 and the chemotactic host defence
(antimicrobial) peptide defensin-b-1 (DEFB1) in IRAK4-
deficient monocytes (Figure 4, Table 1) contrasted the
compromised expression of the chemokines IL-8 (neu-
trophil chemoattractant), Gro-a/CXCL1 (neutrophil che-
moattractant), MCP-2/CCL8 (monocyte, lymphocyte,
basophil, eosinophil chemoattractant) and MIP-3a/
CCL20 (lymphocyte chemoattractant) (Table 1). The
expression of MDC/CCL22 was found to be restricted
to CD14+ PBMC (monocytes) and expression in IRAK4-
deficient monocytes was equivalent to or greater than
expression in control monocytes (Figure 4B). ELISA was
employed to demonstrate that LPS (24 hr) induced the
secretion of 3-fold more MDC (3.3 ± 0.6) by the
patient’s PBMC compared to PBMC from adult or age-
matched children (Figure 4C). Other CC family mem-
bers including MPIF/CCL23 and CCL28 (chemotactic
for monocytes, CD4+ and CD8+ T cells) and the chemo-
kine receptor CXCR3 were also expressed at normal
levels in IRAK4-deficient cells (ArrayExpress E-FPMI-7).
Given that monocytes, dendritic cells, NK cells, and acti-
vated T cells are all chemoattracted by MDC/CCL22,
the heightened expression of this chemokine alone has
the potential to recruit essential immune cells and thus
substantially compensate for the collective absence of
chemokines Gro-a/CXCL1, MCP-2/CCL8, MIP-3a/
CCL20 and IL-8.
Gene expression in IRAK4-deficient monocytes was
subject to transcriptional and translational regulation
Induced genes in LPS-stimulated, IRAK4-deficient
monocytes were likely the result of signal transduction
via the MyD88/IRAK4-independent, TRIF/TRAM-
dependent arm of the TLR4 pathway. Clearly however,
LPS-induced activation of the MyD88/IRAK4-indepen-
dent pathway did not completely compensate for a
defect in the MyD88-dependent pathway, neither in the
Brown et al. Journal of Translational Medicine 2010, 8:6
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number of expressed genes nor magnitude of their
expression.
Kinetic models have estimated that MyD88/IRAK4-
independent activation of NFB via TRIF/TRAM lags
the MyD88-dependent pathway by approximately 30
min [38]. We and others previously demonstrated that
cells from the IRAK4-deficient patient [13,14] and
MyD88-deficient mice [39] do indeed activate NFB
shortly after exposure to LPS. The depletion of cytoplas-
mic pools of NFB as a consequence of nuclear
translocation stimulates new transcription of NFB sub-
units in order to replenish cytoplasmic supplies. This
phenomenon was observed here (Figure 5A, Table 1) for
LPS-activated control monocytes that induced the com-
pensatory expression of all five NFB subunits: NFB1/
p50, NFB2/p52, RelA/p65, RelB and c-Rel. The com-
pensatory expression of all subunits except RelB was
however diminished in IRAK4-deficient cells. The
expression of NFB1/p50 and c-Rel was significantly (p
< 0.05) more impaired after LPS activation than two
Figure 3 Expression of inflammatory cytokines and chemokines in IRAK4-deficient monocytes. A Expression of IL-6, IL-8, IL-12b, TNF-a,
Gro-a/CXCL1 and MIP-3a/CCL20 in the healthy control pooled monocytes (white bars) and in both biological replicates of the patient’s
monocytes (black bars) were evaluated, in duplicate, by qPCR following a 4 hr incubation in the absence or presence of LPS (X-axis). B IL-6, IL-8
and TNF-a were also measured in the tissue culture supernatant of stimulated PBMC by multiplex cytokine bead immunoassays. The Y-axis
represents fold change (log scale) in gene expression relative to unstimulated control monocytes (qPCR) or pg/ml of protein determined by the
cytokine assay. Differences in expression or protein secretion were determined to be statistically significant by Student’s two tailed T-test with a
value of p < 0.15 (*), p < 0.1 (**), p < 0.05 (***) and p < 0.003 (****).
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Table 1 Gene expression by qPCR in resting or LPS-activated IRAK4-deficient monocytes relative to gene expression in
unstimulated control cells
Gene Name Monocytes Resting LPS
DEFB1
Control a1.1 ± 0.6
up
12.6 ± .0
=
IRAK4 Q293X 1.9 ± 0.9 9.6 ± 0.9
Fos
Control 1.5 ± 0.1
=
0.3 ± 0.0
=
IRAK4 Q293X 1.3 ± 0.0 0.3 ± 0.1
Gro-α (CXCL1)
Control 1.0 ± 0.2
dn
6.3 ± 1.2
dn
IRAK4 Q293X 0.3 ± 0.0 0.3 ± 0.0
IL-6
Control 1.1 ± 0.6
dn
185.4 ± 110.0
dn
IRAK4 Q293X 0.4 ± 0.5 1.8 ± 2.1
IL-8
Control 1.0 ± 0.0
=
24.1 ± 5.5
dn
IRAK4 Q293X 0.9 ± 0.8 2.0 ± 1.4
IL-12β
Control 1.0 ± 0.4
dn
181.7 ± 8.0
dn
IRAK4 Q293X 0.2 ± 0.1 1.9 ± 0.8
IL-13RA1
Control 1.0 ± 0.1
=
0.3 ± 0.0
up
IRAK4 Q293X 1.1 ± 0.3 1.9 ± 0.1
IFN-γ
Control 1.0 ± 0.1
dn
11.0 ± 0.3
dn
IRAK4 Q293X 0.4 ± 0.1 0.8 ± 0.3
IRF1
Control 1.0 ± 0.1
dn
6.7 ± 0.1
dn
IRAK4 Q293X 0.6 ± 0.1 3.1 ± 0.2
IκBζ
Control 1.1 ± 0.5
dn
1.3 ± 0.3
dn
IRAK4 Q293X 0.4 ± 0.2 0.5 ± 0.1
Jun
Control 1.0 ± 0.0
=
0.9 ± 0.2
up
IRAK4 Q293X 0.9 ± 0.3 1.7 ± 0.4
MCP-2 (CCL8)
Control 1.0 ± 0.0
dn
9.4 ± 0.0
dn
IRAK4 Q293X 0.1 ± 0.0 1.8 ± 0.2
MDC (CCL22)
Control 1.1 ± 0.5
dn
4.1 ± 1.2
up
IRAK4 Q293X 0.6 ± 0.2 6.4 ± 1.8
MIP-3α (CCL20)
Control 1.0 ± 0.2
dn
83.9 ± 0.0
dn
IRAK4 Q293X 0.1 ± 0.0 1.4 ± 0.5
NFκB1 (p105/p50)
Control 1.0 ± 0.1
dn
6.8 ± 0.1
dn
IRAK4 Q293X 0.3 ± 0.1 2.3 ± 0.7
NFκB2 (p100/p52)
Control 1.0 ± 0.0
dn
4.5 ± 0.7
dn
IRAK4 Q293X 0.7 ± 0.0 1.9 ± 0.3
NFκB cRel
Control 1.0 ± 0.1
dn
3.8 ± 0.1
dn
IRAK4 Q293X 0.7 ± 0.0 1.0 ± 0.0
NFκB RelA (p65)
Control 1.0 ± 0.0
=
3.3 ± 0.2
dn
IRAK4 Q293X 1.2 ± 0.0 2.3 ± 0.4
NFκB RelB
Control 1.0 ± 0.2
=
1.9 ± 0.4
=
IRAK4 Q293X 0.8 ± 0.0 1.7 ± 0.3
SOCS1
Control 1.2 ± 0.8
dn
21.2 ± 4.7
dn
IRAK4 Q293X 0.1 ± 0.1 1.6 ± 0.5
TNF-α
Control 1.0 ± 0.1
=
11.3 ± 4.0
dn
IRAK4 Q293X 0.9 ± 0.6 2.4 ± 0.7
ZFP36L2
Control 1.0 ± 0.1
up
0.8 ± 0.0
up
IRAK4 Q293X 2.1 ± 0.5 2.1 ± 0.2
a fold changes normalized to endogenous GAPDH in patient or control cells then expressed relative to that in the pool of unstimulated control monocytes (fold
change = 1.0) ± the standard deviation of 2 biological and 2 technical replicates.
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other subunits (NFB2/p52 and RelA/p65). Likewise,
IBζ, a LPS-inducible regulator of NFB that is required
for IL-6 transcription [40] was expressed at sub par
levels in IRAK4-deficient monocytes (Figure 5A, Table
1), which correlated with the compromised expression
of IL-6 (Figure 3, Table 1). These data offer evidence
that an initial wave of normal NFB activation and gene
transcription in IRAK4-deficient cells (via the TRIF/
TRAM pathway) [13,14] would be prematurely trun-
cated due to a substantial deficit in the ability of NFB
to induce its own compensatory transcription in
response to LPS.
The expression of cytokines, chemokines and tran-
scription factors is also heavily dependent on the stabi-
lity of transcribed mRNA. AU-rich elements (ARE) are
found near the 3’ untranslated region (UTR) of these
mRNAs and target the message for degradation. The
zinc finger protein ZFP36L2, a relative of the prototy-
pic Zinc-finger protein tristetraprolin/TTP, targets the
ARE region of TNF-a mRNA, destabilizes the
sequence and prevents secretion of TNF-a [41]. The
expression of ZFP36L2 was elevated greater than 2-
fold in IRAK4-deficient monocytes compared to con-
trol monocytes (Figure 5B, Table 1), a result consistent
with the compromised expression of TNF-a mRNA
and protein (Figure 3). Another negative regulator of
TNF-a, IL-13RA1, was upregulated more than 6-fold
in LPS-stimulated IRAK4-deficient monocytes (Figure
5B, Table 1). IL-13RA1 mediates translational repres-
sion of TNF-a mRNA in LPS-stimulated monocytes
and is required for IL-13-mediated protection of mice
from lethal endotoxemia [42]. Other mRNA (de)stabili-
zation agents may be direct or indirect substrates of
IRAK4, for example, the MAPKs that also act on ARE-
binding proteins such as TTP were severely impaired
in IRAK4-KD BMDM [37].
These results suggest that the expression of NFB-
regulated genes in IRAK4-deficient cells results from the
combined contribution of transcriptional regulation of
the gene itself as well as that of other genes that encode
elements that influence transcriptional longevity (e.g.,
NFB) and mRNA stability (e.g., ZFP36L2, IL-13RA1).
These data offer an explanation for the variable expres-
sion, rather than abolishment, of mRNA/protein of var-
ious cytokines and chemokines in IRAK4-deficient cells.
Furthermore, these data demonstrated that the observed
gene expression is regulated and the reciprocal relation-
ships between certain genes (e.g., over-expression of
ZFP36L2 & IL13RA1 with repression of TNF-a) is pre-
served, albeit in an unbalanced state compared to
IRAK4-competent cells. These data indicate that an
initial, but perhaps not subsequent waves of inflamma-
tory mediators are produced in the absence of IRAK4, a
result that is in line with a previous suggestion that
IRAK4 may only become important in the face of a sus-
tained bacterial challenge [37].
Discussion
Individuals with defects in key immunity genes, while
rare, represent valuable models for understanding the
immune system and disease pathogenesis in humans.
Sub-optimal expression of particular TLR-responsive
genes has become an accepted hallmark of a primary
immunodeficiency and a predisposition to infection. In
contrast to previous studies that evaluated a selected
subset of immunity genes, this study employed microar-
ray technology to evaluate the impact of an IRAK4-defi-
ciency on 21 K human genes. The absence of IRAK4
compromised the appropriate expression of 567 LPS-
responsive genes in human monocytes, including a
broad array of genes (pro-inflammatory interleukins,
CXC and CC chemokines, and NFB subunits)
Figure 4 Strong expression of particular chemokines in IRAK4-deficient monocytes. The relative expression (Y-axis) of (A) DEFB1 and (B)
MDC/CCL22 in IRAK4-deficient monocytes (black bars), controls (white bars) and for B) CD14- PBMC. Expression was measured in two
independent experiments by real-time PCR following 4 hr incubation in the absence or presence of LPS (X-axis). C MDC/CCL22 in the tissue
culture supernatant was measured by ELISA in IRAK4-deficient (black bars), adult (white bars) or age-matched (grey bars) PBMC. The result is
representative of 2 independent experiments and the y-axis represents the relative fold change in protein after stimulation for 24 hr with LPS.
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implicated in inflammation and immunity. In accor-
dance with previous analyses on a much smaller subset
of genes and proteins, the global disruption of gene
expression in IRAK4-deficient cells conclusively demon-
strated that IRAK4 plays a pivotal role in transmission
of signals along the TLR4 pathway that culminate in
robust pro-inflammatory gene transcription. Based on
the current belief that robust TLR4-responsiveness is a
requirement for immunity, these data would also have
led us to predict that IRAK4-deficient children would be
highly susceptible to Gram negative infections.
The clinical data, however, indicate that invasive infec-
tion by Gram negative bacteria are at most a rare occur-
rence in IRAK4-deficient children despite severely
compromised responses of IRAK4-deficient cells to LPS.
To confirm this phenotype in a controlled situation, we
utilized IRAK4-deficient mice to quickly ascertain their
ability to survive infection by a Gram negative bacter-
ium in vivo. These mice, like IRAK4-deficient children,
are susceptible to infections by Gram positive bacteria
and fail to produce inflammatory cytokines in response
to LPS [19-24]. We now demonstrate that IRAK4
knockout mice and wildtype mice have a similar resis-
tance to challenge with Gram negative bacteria, thereby
providing strong evidence that effective immunity is
maintained and may account for the relatively few cases
of Gram negative infections in mice and children with
an IRAK4-deficiency.
These data are consistent with the hypothesis that a
robust transcriptional response to LPS is not essential as
long as key aspects of the immune response are main-
tained; such a hypothesis must be qualified given that
the complete absence of such responses in MyD88
knockout mice does influence susceptibility to Gram
negative infections. Such subtle changes in the elements
of the immune system, including for e.g., polymorph-
isms in certain genes are becoming increasingly recog-
nized as sufficient to alter immunity [43]. For example
only 250 genes are included within the major locus of
variability between S. pneumoniae-sensitive and -resis-
tant strains of mice [44]. During the course of this
study, we also evaluated the transcriptional responsive-
ness of IRAK4-deficient cells to peptidoglycan (PGN).
This component of the cell wall of Gram positive bac-
teria stimulates several innate immunity receptors,
including TLR2. Despite a predisposition of IRAK4-defi-
cient children to Gram positive infections, we observed
relatively normal transcriptional responses of IRAK4-
deficient monocytes to PGN (data included in ArrayEx-
press E-FPMI-7). These data also suggested to us that
immunity is quite complex and cannot necessarily be
inferred from even a global assessment of agonist-
induced transcriptional responses.
If one accepts at least a portion of the prevailing
dogma and assumes that essential elements of Gram
negative immunity are contained within the transcrip-
tional response to LPS, it is possible to speculate, based
on the data provided here, that these key elements
either (1) include classical pro-inflammatory cytokines
and chemokines that adequately perform immunological
function(s) at reduced concentrations (e.g., TNF-a, IL-6)
or (2) are contained within the subset of genes that
were expressed to similar levels in IRAK4-deficient and
Figure 5 Differential regulation of elements that regulate gene
transcription and translation in IRAK4-deficient monocytes. The
relative expression (Y-axis) of (A) NFB subunits NFB1 (p105/50),
NFB2 (p100/52), RelA (p65), RelB & c-Rel, NFB regulator IBζ, and
(B) translational suppressors IL-13RA & ZFP36L2 in IRAK4-deficient
monocytes (black bars) and controls (white bars) was measured by
real-time PCR following 4 hr incubation in the absence or presence
of LPS (X-axis). Results show gene expression relative to
unstimulated control monocytes and are representative of 3
independent experiments. Differences in expression were
determined to be statistically significant by Student’s two tailed T-
test with a value of p < 0.15 (*), p < 0.1 (**), p < 0.05 (***) or p <
0.01 (****).
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control monocytes (e.g., MDC/CCL22, DEFB1). Consis-
tent with these concepts, it was recently demonstrated
that innate defence regulator peptides, which suppress
pro-inflammatory cytokines but substantially maintain
chemokine responses, are able to protect against Salmo-
nella infections [30]. The functional redundancy of che-
mokines is an example of how the expression of just a
few genes might be sufficient to support critical immu-
nological functions such as cellular recruitment, despite
the severe impairment of the expression of other family
members. As demonstrated here, the expression of IL-8/
CXCL8, Gro-a/CXCL1, MCP-2/CCL8 and MIP-3a/
CCL20 was compromised in LPS-stimulated IRAK4-
deficient monocytes (Figure 3, Table 1), suggesting a
diminished recruitment of neutrophils, monocytes, lym-
phocytes, basophils and eosinophils to sites of infection.
However, the chemokines MDC/CCL22, MPIF/CCL23,
CCL28 and DEFB1 were robustly expressed in the
absence of IRAK4 (Figure 5 and ArrayExpress), implying
that monocytes, dendritic cells, natural killer cells, mem-
ory T cells, and activated CD4+ and CD8+ T cells, parti-
cularly CD4+ T-helper-2 (Th2) cells could still be
mobilized in response to LPS. The enhanced recruit-
ment of Th2 cells that express IL-4 and IL-13 would be
consistent with the elevated expression of IL-13RA1
(Figure 5), as well as reports of relatively normal anti-
body responses to vaccination in some children with
IRAK4-deficiency [15,16]. Similar to our findings in
human IRAK4-deficient monocytes, a number of che-
mokines were expressed at similar levels in murine
BMDM from wildtype and IRAK4-kinase-defective
knock-in mice, such as CXCL2, CXCL10, CXCL11,
CCL2 and CCL4 [Clusters I and III in [37]]. We propose
that the observed differential expression of chemokines
is sufficient to appropriately change the cellular milieu
at the site of infection and favourably impact on the
outcome to infection [45]. Without supporting in vivo
data however, these results are at best speculative. It
should however be noted that infections in patients with
IRAK4-deficiency are pyogenic (pus-forming) and can
lead to mild fever and inflammation at late stages of
infection [12]. This in vivo evidence implies that certain
inflammatory mediators must have been produced and
that cells are actively recruited to the site of infection in
IRAK4-deficient individuals. Furthermore, TNFa and
IL-6 were detected, albeit at low levels in the serum of
IRAK4-KD mice following administration of LPS [37].
Other potential candidate elements that might mediate
defence include the >60 upregulated genes and 20 down
regulated genes listed in Table S1, Additional file 1
(genes with similar or exaggerated expression in IRAK4-
deficient cells compared to controls). Some of these
genes in the ADAM, ICAM, integrin and NFB families
were also regulated in a similar fashion in IRAK4-KD
and control BMDM stimulated with LPS [37]. Although
GO analysis did not predict a disturbance in any major
biological process in resting (unstimulated) IRAK4-defi-
cient monocytes, we identified more than 50 LPS-
responsive genes that were expressed in resting IRAK4-
deficient cells not exposed to LPS (Table S2, Additional
file 2). Notable genes include cytokines & chemokines
(IL1F9, MIP-2a/CXCL2), transcription factors & tran-
scriptional regulators (c-REL, NFKB1A, IBRDC2,
UBE2N, USP9Y, BACH1), cell adhesion molecules
(CD44), signalling molecules (MAPK6, PRKAG2,
CALM3) and other pro-inflammatory mediators
(ALOX5, HIF3a, HLA-DMA, LILRA3). It is tempting
speculate that these differentially expressed genes in
unstimulated, IRAK4-deficient cells may also contribute
to successful host defences.
LPS-induced gene expression in IRAK4-deficient cells
is subject to regulation by both transcriptional and
translational mechanisms and is the product of signal
transduction via either (1) the MyD88-independent,
TRIF/TRAM pathway or (2) MyD88-dependent, IRAK4-
independent pathways. Björkbacka and colleagues have
demonstrated that only 20% of more than 1000 LPS-
responsive genes in macrophages are in fact dependent
on MyD88 [46]. We however favour the hypothesis that
a subset of MyD88-dependent, IRAK4-independent
genes are imperative for immunity since MyD88-defi-
cient mice are susceptible to a broader range of patho-
gens, including Gram negative bacteria, than are caused
by IRAK4-deficiency in mice and humans. MyD88-
dependent pathways that transduce signals independent
of IRAK4 utilize signalling molecules such as PI3K, Btk,
Tlp-2, and NIK and activate MAPKs and NFB. Regard-
less, it can be concluded that pathways other than the
classic MyD88-dependent pathway (via sequential acti-
vation of IRAK4, IRAK1, TRAF6, IKK and NFB) have
essential and under-appreciated roles in defence against
Gram negative bacteria.
Conclusions
In this study, we demonstrated that the expression of
the vast majority of LPS-induced inflammatory and
immunity genes were compromised (compared to the
expression levels in control cells) in monocytes from a
child with IRAK4 deficiency. We conclude that while
IRAK4 is imperative for a comprehensive transcriptional
response to LPS, neither IRAK4, nor this classical,
robust transcriptional response is required for effective
host defences against Gram negative infection. Instead,
the data implies that sufficient defence could lie within
a small repertoire of LPS-responsive, IRAK4-indepen-
dent genes. A subset of transcribed genes amidst a
severely impaired response to LPS was also observed by
Koziczak-Holbro et al in murine BMDM from IRAK4-
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kinase-defective knockin mice [37]. These observations
are consistent with the concept that it may be possible
to generate an effective immune response without a
robust inflammatory response [47] and such properties
may even make IRAK4 an attractive drug target for
treating inflammation without compromising effective
immune defences [48].
Additional file 1: Table S1. Selection of LPS-responsive immunity genes
that were expressed to similar or exaggerated (italics) levels in IRAK4-
deficient monocytes compared to controls as assayed by microarray
analysis
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1479-5876-8-6-
S1.PDF ]
Additional file 2: Table S2. Selection of LPS-responsive genes expressed
in unstimulated IRAK4-deficient monocytes
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1479-5876-8-6-
S2.PDF ]
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